新辅助化疗与机器人辅助根治性膀胱切除术后围手术期不良结局无关:IRCC 数据支持扩大使用
基于国际机器人膀胱切除联盟(IRCC)2006–2017 年回顾性数据,298 例(26%)接受新辅助化疗的非转移性肌层浸润性尿路上皮癌患者,其新辅助化疗使用率从 2006–2007 年的 10% 升至 2016–2017 年的 42%(p<0.01)。多因素分析显示新辅助化疗与手术时间延长、住院时间、90 天并发症、再手术或死亡率无显著关联,但与 90 天再入院相关(OR 5.90,95%CI 3.30–10.90,p<0.01)。
要点
- 新辅助化疗使用率十年间从 10% 显著增至 42%。
- 新辅助化疗未增加 90 天并发症、再手术或死亡风险。
- 新辅助化疗与 90 天再入院风险升高独立相关(OR 5.90)。
核心结论
- 新辅助化疗未与机器人辅助根治性膀胱切除术后的围手术期手术并发症相关。
研究设计与样本
- 回顾性队列研究,基于 IRCC 数据库 2006–2017 年数据,排除非肌层浸润性膀胱癌后比较接受与未接受新辅助化疗的患者。
主要发现
- 298 例(26%)接受新辅助化疗,其年龄更轻(67 vs 69 岁,p=0.01),ASA 评分≥3 比例更高(62% vs 55%,p=0.02),病理 T3 及以上分期比例更高(28% vs 22%,p=0.04)。
- 新辅助化疗使用率从 2006–2007 年的 10% 增至 2016–2017 年的 42%(p<0.01)。
- 多因素分析显示新辅助化疗与手术时间延长、住院时间、90 天术后并发症、再手术或死亡率无显著关联。
- 新辅助化疗与 90 天再入院相关(OR 5.90,95%CI 3.30–10.90,p<0.01)。
临床怎么用
- 对于适合的非转移性肌层浸润性膀胱癌患者,机器人辅助根治性膀胱切除术前可考虑新辅助化疗而不必担心增加围手术期手术并发症。
- 新辅助化疗后需关注 90 天再入院风险,加强术后随访与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to determine the trend of neoadjuvant chemotherapy use for nonmetastatic muscle invasive urothelial bladder cancer and whether it is associated with adverse perioperative morbidity after robot-assisted radical cystectomy. MATERIALS AND METHODS: We retrospectively reviewed the IRCC (International Robotic Cystectomy Consortium) database between 2006 and 2017. After excluding patients with nonmuscle invasive bladder cancer the patients were divided into 2 groups, including those who did vs did not receive neoadjuvant chemotherapy. Data were reviewed for demographics, preoperative, operative and 90-day perioperative outcomes. We used the Cochran-Armitage trend test to assess trends of neoadjuvant chemotherapy associations with high grade and overall complications with time. Multivariate stepwise regression analyses were done to determine whether neoadjuvant chemotherapy was associated with prolonged operative time, 90-day postoperative complications, readmissions, reoperations and mortality after robot-assisted radical cystectomy. RESULTS: A total of 298 patients (26%) received neoadjuvant chemotherapy. These patients were younger (age 67 vs 69 years, p=0.01) and more frequently had an ASA™ (American Society of Anesthesiologists™) score of 3 or greater (62% vs 55%, p=0.02) and pathological T3 stage or greater disease (28% vs 22%, p=0.04). The use of neoadjuvant chemotherapy increased significantly from 10% in 2006 to 2007 to 42% in 2016 to 2017 (p <0.01). On multivariate analysis neoadjuvant chemotherapy was not significantly associated with prolonged operative time, hospital stay, 90-day postoperative complications, reoperation or mortality. Neoadjuvant chemotherapy was associated with 90-day readmissions after robot-assisted radical cystectomy (OR 5.90, 95% CI 3.30-10.90, p <0.01). CONCLUSIONS: Neoadjuvant chemotherapy utilization has significantly increased in the last decade. It was not associated with perioperative surgical morbidity after robot-assisted radical cystectomy.
引用
- Aldhaam NA, Elsayed AS, Jing Z, et al. Neoadjuvant Chemotherapy is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Use from the IRCC. J Urol. 2019. PMID: 31600114. doi:10.1097/JU.0000000000000445
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。